Mitoparan [L14T], Mastoparan [A5,8K;A10Aib;L14T]

General Information


DRACP ID  DRACP03809

Peptide Name   Mitoparan [L14T], Mastoparan [A5,8K;A10Aib;L14T]

Sequence  INLKKLAKLXKKIT

Sequence Length  14

UniProt ID  P01514 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C71H133N19O15

Absent amino acids  CDEFGHMPQRSVWY

Common amino acids  K

Mass  183503

Pl  11.4

Basic residues  5

Acidic residues  0

Hydrophobic residues  6

Net charge  5

Boman Index  -1055

Hydrophobicity  -10.71

Aliphatic Index  146.43

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 29337270

Title  The cationic tetradecapeptide mastoparan as a privileged structure for drug discovery: Enhanced antimicrobial properties of mitoparan analogues modified at position-14

Doi Not available

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  12798

DRACP is developed by Dr.Zheng's team.